Skip to main content
. Author manuscript; available in PMC: 2015 May 22.
Published in final edited form as: Digestion. 2014 May 22;89(3):216–224. doi: 10.1159/000360791

Figure 5.

Figure 5

Therapeutic Deletion of CAF in CCA. In the course of tumorigenesis, stromal fibroblasts acquire a modified phenotype and become activated or primed for apoptosis. Navitoclax, a BH-3 mimetic, causes apoptotic cell death in activated CAFs [46]. This targeted deletion of CAFs leads to secondary cancer cell apoptosis and reduction in tumor size.